Cell Theranostics is a late-stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases.
The company acquired five platform technologies that are in late-stage development from The University of Texas M.D. Anderson Cancer Center.
Cell Theranostics’ lead product in clinical development is ethylenedicysteine-glucosamine which the Company registered under the trademark “Oncardia”. With applications in cancer and cardiovascular disease, Oncardia can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic product compounds. Oncardia is able to target the diseased cell where it is fully phosphorylated and enters the cell nucleus. This enables Oncardia to serve as a uniquely effective diagnostic and therapeutic platform for drug development and clinical applications. Oncardia can be conveniently labeled with technetium-99m (99mTc) for imaging with SPECT and SPECT/CT camera systems or gallium-68 (68Ga) for imaging with PET and PET/CT camera systems. For therapy, Oncardia can be complexed with a cold metal for intra-nuclear metallic therapy such as platinum or rhenium-187 (187Re), or it can be labeled with radionuclides like lutetium-177 (177Lu) or rhenium-188 (188Re) for intra-nuclear radiotherapy.
Platform Technologies Acquired from the University of Texas M.D. Anderson Cancer Center
Platform Technologies Are Based on Chelation Chemistry
Molecular Imaging Agents
Targeted Intra-Nuclear Therapeutics
Patents Granted Worldwide
Theranostic medicine is a major step forward in making personalized medicine a reality. It is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level.Explore
Before the development of FDG-PET/CT, medical oncologists were limited to standard X-ray, CT, MRI, Ultrasound and some utilization of nuclear imaging. FDG-PET/CT ushered in a new approach to cancer diagnostics by creating 3-D images at the molecular level. Oncardia has the potential to shift the paradigm to a more accurate, accessible, and cost-effective way to diagnose and stage cancer without the drawbacks of FDG used in PET-CT imaging.Explore
Nuclear cardiology needs an agent that eliminates the drawbacks associated with perfusion imaging to diagnose the presence and extent of myocardial ischemia. . At Cell Theranostics we are making that a reality.Explore
MedAxiom Announces Industry Partnership With Cell>Point with Video Cell>Point, improving lives through imaging and targeted therapy. Partner News…Read
CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…Read
CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…Read
CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…Read